Bullfrog AI, LIBD reveal new insights into bipolar disorder pathways

BullFrog AI Holdings announced significant advancements in its ongoing collaboration with the Lieber Institute for Brain Development, LIBD. Building on the progress detailed in our May 16, 2024 release, the company’s research has now pinpointed specific molecular pathways associated with bipolar disorder, enabling the identification of new candidate drug targets. The company’s latest analysis, focusing on functional enrichment across various brain regions associated with bipolar disorder, identified significant enrichment in six out of 68 clusters from the LIBD brain dataset. This means that six specific groups of genes or proteins, which are highly relevant to at least some cases with BD, were found among the many brain data clusters analyzed. This is significant because it narrows down gene networks most involved in BD, allowing for more targeted research.